# Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

> **NCT02268695** · PHASE2 · COMPLETED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 541 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** 5-Fluorouracile
- **DRUG:** Docetaxel
- **DRUG:** Cetuximab
- **DRUG:** granulocyte colony-stimulating factor (G-CSF)

## Key facts

- **NCT ID:** NCT02268695
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-10
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 541 (ACTUAL)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268695, "Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02268695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*